Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has received five new patents in Canada, Australia, New Zealand, Brazil and Lebanon.

The patents provide additional protection for Generex's proprietary compositions and methodologies for delivering pharmaceuticals in buccal applications. With the addition of these patents, Generex now holds an aggregate of 146 patents worldwide, including 21 in the United States, and has an aggregate of 116 patent applications pending in various jurisdictions throughout the world.

Commenting on the patent awards, Anna Gluskin, the company's president & chief executive officer, stated, "Generex continues to bolster its intellectual property as we begin to commercialize our revolutionary drug delivery systems throughout the world. We have invested significant resources in developing and protecting our processes and these patents represent another step forward as we continue toward building a solid foundation for the future of our company."

The Canadian Intellectual Property Office granted the company its tenth Canadian patent, titled 'Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application'. The patent contains composition and process claims to pharmaceutical compositions comprising macromolecule pharmaceuticals in micellar form effective in buccal and pulmonary applications.

The Intellectual Property Office of Australia granted the Company a patent titled 'Methods of Administering and Enhancing Absorption of Pharmaceutical Agents'. This is the fifth Australian patent granted to the Company.

The Intellectual Property Office of New Zealand granted the company a patent titled 'Composition and Method for Raising Blood Glucose Level'.

The National Institute of Industrial Property in Brazil granted the company a patent titled 'Mixed Micellar Delivery System and Method of Preparation'. The patent contains formulation claims to an improved delivery system for the administration of large molecule pharmaceuticals which may be administered through the oral and nasal membranes. This is the company's first Brazilian patent.

The patent titled 'Pharmaceutical Formulation, Uses of Metered Dose Dispenser Containing Same' was granted to the Company by the Lebanese Intellectual Property Office. The patent contains method, formulation and metered dose dispenser claims for a pharmaceutical formulation for absorption through oral mucosae in mixed micellar form.

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.